

Massimo Tortarolo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8654533/publications.pdf>

Version: 2024-02-01

38
papers

1,904
citations

257450

24
h-index

330143

37
g-index

38
all docs

38
docs citations

38
times ranked

2741
citing authors

#	ARTICLE	IF	CITATIONS
1	Mutant Copper-Zinc Superoxide Dismutase (SOD1) Induces Protein Secretion Pathway Alterations and Exosome Release in Astrocytes. <i>Journal of Biological Chemistry</i> , 2013, 288, 15699-15711.	3.4	216
2	Transgenic SOD1 G93A mice develop reduced GLT Δ 1 in spinal cord without alterations in cerebrospinal fluid glutamate levels. <i>Journal of Neurochemistry</i> , 2001, 79, 737-746.	3.9	173
3	Persistent activation of p38 mitogen-activated protein kinase in a mouse model of familial amyotrophic lateral sclerosis correlates with disease progression. <i>Molecular and Cellular Neurosciences</i> , 2003, 23, 180-192.	2.2	155
4	Functional alterations of the ubiquitin-proteasome system in motor neurons of a mouse model of familial amyotrophic lateral sclerosis. <i>Human Molecular Genetics</i> , 2009, 18, 82-96.	2.9	146
5	Glutamate AMPA receptors change in motor neurons of SOD1G93A transgenic mice and their inhibition by a noncompetitive antagonist ameliorates the progression of amyotrophic lateral sclerosis-like disease. <i>Journal of Neuroscience Research</i> , 2006, 83, 134-146.	2.9	104
6	Activation of the p38MAPK cascade is associated with upregulation of TNF alpha receptors in the spinal motor neurons of mouse models of familial ALS. <i>Molecular and Cellular Neurosciences</i> , 2006, 31, 218-231.	2.2	92
7	Lack of apoptosis in mice with ALS. <i>Nature Medicine</i> , 1999, 5, 966-967.	30.7	90
8	Activated p38MAPK Is a Novel Component of the Intracellular Inclusions Found in Human Amyotrophic Lateral Sclerosis and Mutant SOD1 Transgenic Mice. <i>Journal of Neuropathology and Experimental Neurology</i> , 2004, 63, 113-119.	1.7	81
9	Proteomic analysis of spinal cord of presymptomatic amyotrophic lateral sclerosis G93A SOD1 mouse. <i>Biochemical and Biophysical Research Communications</i> , 2007, 353, 719-725.	2.1	72
10	Glutamate release in human cerebral cortex and its modulation by 5-hydroxytryptamine acting at h 5-HT 1D receptors. <i>British Journal of Pharmacology</i> , 1998, 123, 45-50.	5.4	61
11	Expression of SOD1 G93A or wild-type SOD1 in primary cultures of astrocytes downregulates the glutamate transporter GLT Δ 1: lack of involvement of oxidative stress. <i>Journal of Neurochemistry</i> , 2004, 88, 481-493.	3.9	57
12	New Insights on the Mechanisms of Disease Course Variability in ALS from Mutant SOD1 Mouse Models. <i>Brain Pathology</i> , 2016, 26, 237-247.	4.1	56
13	Amyotrophic Lateral Sclerosis, a Multisystem Pathology: Insights into the Role of TNF Mediators of Inflammation, 2017, 2017, 1-16.	3.0	45
14	Inter- and Intracellular Signaling in Amyotrophic Lateral Sclerosis: Role of p38 Mitogen-Activated Protein Kinase. <i>Neurodegenerative Diseases</i> , 2005, 2, 128-134.	1.4	42
15	Targeting Extracellular Cyclophilin A Reduces Neuroinflammation and Extends Survival in a Mouse Model of Amyotrophic Lateral Sclerosis. <i>Journal of Neuroscience</i> , 2017, 37, 1413-1427.	3.6	42
16	Lack of TNF Δ alpha receptor type 2 protects motor neurons in a cellular model of amyotrophic lateral sclerosis and in mutant SOD1 mice but does not affect disease progression. <i>Journal of Neurochemistry</i> , 2015, 135, 109-124.	3.9	33
17	RNS60 exerts therapeutic effects in the SOD1 ALS mouse model through protective glia and peripheral nerve rescue. <i>Journal of Neuroinflammation</i> , 2018, 15, 65.	7.2	33
18	Specific Induction of Akt3 in Spinal Cord Motor Neurons is Neuroprotective in a Mouse Model of Familial Amyotrophic Lateral Sclerosis. <i>Molecular Neurobiology</i> , 2014, 49, 136-148.	4.0	32

#	ARTICLE	IF	CITATIONS
19	Differential Expression of S100 β and Glial Fibrillary Acidic Protein in the Hippocampus after Kainic Acid-Induced Lesions and Mossy Fiber Sprouting in Adult Rat. <i>Experimental Neurology</i> , 2000, 161, 317-329.	4.1	31
20	Unraveling the Complexity of Amyotrophic Lateral Sclerosis: Recent Advances from the Transgenic Mutant SOD1 Mice. <i>CNS and Neurological Disorders - Drug Targets</i> , 2010, 9, 491-503.	1.4	31
21	Talampanel reduces the level of motoneuronal calcium in transgenic mutant SOD1 mice only if applied presymptomatically. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2011, 12, 340-344.	2.1	30
22	Biocompatible fluorescent nanoparticles for <i>in vivo</i> stem cell tracking. <i>Nanotechnology</i> , 2013, 24, 245603.	2.6	29
23	Multiple intracerebroventricular injections of human umbilical cord mesenchymal stem cells delay motor neurons loss but not disease progression of SOD1G93A mice. <i>Stem Cell Research</i> , 2017, 25, 166-178.	0.7	29
24	Expression of glutamate receptor subtypes in the spinal cord of control and mnd mice, a model of motor neuron disorder. <i>Journal of Neuroscience Research</i> , 2002, 70, 553-560.	2.9	25
25	Lentiviral vectors carrying enhancer elements of Hb9 promoter drive selective transgene expression in mouse spinal cord motor neurons. <i>Journal of Neuroscience Methods</i> , 2012, 205, 139-147.	2.5	23
26	Erythropoietin does not preserve motor neurons in a mouse model of familial ALS. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2007, 8, 31-35.	2.1	21
27	Human SOD1-G93A Specific Distribution Evidenced in Murine Brain of a Transgenic Model for Amyotrophic Lateral Sclerosis by MALDI Imaging Mass Spectrometry. <i>Journal of Proteome Research</i> , 2014, 13, 1800-1809.	3.7	21
28	Glial activation and TNFR-I upregulation precedes motor dysfunction in the spinal cord of mnd mice. <i>Cytokine</i> , 2004, 25, 127-135.	3.2	20
29	Altered Metabolic Profiles Associate with Toxicity in SOD1G93A Astrocyte-Neuron Co-Cultures. <i>Scientific Reports</i> , 2017, 7, 50.	3.3	20
30	Longitudinal tracking of triple labeled umbilical cord derived mesenchymal stromal cells in a mouse model of Amyotrophic Lateral Sclerosis. <i>Stem Cell Research</i> , 2015, 15, 243-253.	0.7	19
31	Spinal Cord Metabolic Signatures in Models of Fast- and Slow-Progressing SOD1G93A Amyotrophic Lateral Sclerosis. <i>Frontiers in Neuroscience</i> , 2019, 13, 1276.	2.8	14
32	A Mouse Model of Familial ALS Has Increased CNS Levels of Endogenous Ubiquinol9/10 and Does Not Benefit from Exogenous Administration of Ubiquinol10. <i>PLoS ONE</i> , 2013, 8, e69540.	2.5	14
33	Kif1B β isoform is enriched in motor neurons but does not change in a mouse model of amyotrophic lateral sclerosis. <i>Journal of Neuroscience Research</i> , 2003, 71, 732-739.	2.9	12
34	Targeting Stress Activated Protein Kinases, JNK and p38, as New Therapeutic Approach for Neurodegenerative Diseases. <i>Central Nervous System Agents in Medicinal Chemistry</i> , 2006, 6, 109-117.	1.1	12
35	A Novel HGF/SF Receptor (MET) Agonist Transiently Delays the Disease Progression in an Amyotrophic Lateral Sclerosis Mouse Model by Promoting Neuronal Survival and Dampening the Immune Dysregulation. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8542.	4.1	8
36	The p97 β Nplc4 ATPase complex plays a role in muscle atrophy during cancer and amyotrophic lateral sclerosis. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2022, 13, 2225-2241.	7.3	7

#	ARTICLE	IF	CITATIONS
37	Presymptomatically applied AMPA receptor antagonist prevents calcium increase in vulnerable type of motor axon terminals of mice modeling amyotrophic lateral sclerosis. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2017, 1863, 1739-1748.	3.8	5
38	Translational Research in ALS. , 2008, , 267-310.		3